Clinical trials: Filovirus Infections
Ebola Disease, Marburg Disease
A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN(R)-Filo and Ad26.ZEBOV administered in different sequences at…
- Trial name
- NCT02891980
- Testing
- Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Hemorrhagic Fever
Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6002, a post-exposure prophylaxis candidate treatment for Ebolavirus.
- Trial name
- NCT01353027
- Testing
- AVI-6002
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
This is a phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study with additional multiple-ascending dose cohorts in healthy male and female volunteers.
- Trial name
- NCT01518881
- Testing
- TKM-100201
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Marburg Virus Disease
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
- Trial name
- NCT07425821
- Testing
- rVSV∆G-MARV-GP
- Where
- 2 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Ebola Virus Disease
Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults
The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.
- Trial name
- NCT02718469
- Testing
- Ebola Vaccine - low dose, Ebola Vaccine - mid dose, Ebola Vaccine - high dose
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Auro Vaccines LLC
Ebola Vaccines
A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
The objective of this trial is to assess in healthy adults the safety and reactogenicity of a new candidate vaccine, cAd3-EBOZ, made of a chimpanzee Adenovirus vector encoding the glycoprotein of Zaire Ebola virus.
- Trial name
- NCT02289027
- Testing
- cAd3-EBOZ vaccine
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Hemorrhagic Fever, Ebola, Healthy
Experimental Ebola Vaccine Trial
This study will test the safety of an experimental vaccine developed to protect against Ebola virus infection and to determine if the vaccine induces an immune response to the virus.
- Trial name
- NCT00072605
- Testing
- VRC-EBODNA012-00-VP
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hemorrhagic Fever, Ebola
Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.
- Trial name
- NCT02661464
- Testing
- Ad26.ZEBOV, MVA-BN-Filo
- Where
- 16 sites in United States, Burkina Faso and 5 more
- Volunteers
- 677 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Marburg Virus Disease
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics of galidesivir following administration of single doses by IV infusion
- Trial name
- NCT03800173
- Testing
- galidesivir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Hemorrhagic Fever, Ebola
Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda
Phase Ib study in 90 healthy adults,18 years to 65 years of age, to evaluate the safety, tolerability and immunogenicity of the VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ) investigational Ebola vaccines in…
- Trial name
- NCT02354404
- Testing
- cAd3-EBOZ, cAd3-EBO, MVA-EbolaZ
- Where
- Uganda
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC
The goal of this randomized controlled trial is to investigate whether individuals in DRC previously vaccinated with Zabdeno/Mvabea® or Ervebo® vaccine schedules against Ebola virus can be safely and adequately boosted with…
- Trial name
- EBO-BOOST (NCT06126822)
- Testing
- Zabdeno® booster, Ervebo® booster
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Marburg Hemorrhagic Fever
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7288 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
- Trial name
- NCT01566877
- Testing
- AVI-7288
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Healthy
An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola
This Phase I clinical trial was developed to study drug safety, tolerability, and pharmacokinetics of the medicine for Ebola fever emergency prevention based on monoclonal recombinant antibodies in single use in healthy…
- Trial name
- 03-AT-2017 (NCT03428347)
- Testing
- GamEMab
- Where
- Russia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Marburg Virus Disease (MVD)
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy Adult Participants
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1519
- Trial name
- NCT07919210
- Testing
- mRNA-1519
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Ebola Virus Disease
A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain…
- Trial name
- NCT02533791
- Testing
- 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV), 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Ebola Virus Disease
A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.
This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between…
- Trial name
- NCT02401373
- Testing
- Ad5-EBOV
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Ebola Virus Disease
Partnership for Research on Ebola VACcinations
The purpose of this study is to evaluate the safety and immunogenicity of three vaccine strategies that may prevent Ebola virus disease (EVD) events in children and adults.
- Trial name
- PREVAC (NCT02876328)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, rVSVΔG-ZEBOV-GP
- Where
- 6 sites in Guinea, Liberia and 2 more
- Volunteers
- 4,789 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM)…
- Trial name
- NCT03929757
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- 2 sites in Guinea, Sierra Leone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Hemorrhagic Fever
Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
The purpose of this study is to evaluate the post-vaccination immune status at different time points in subjects immunized against Ebola Virus Disease; to select an optimal regimen of product administration; and, to assess safety…
- Trial name
- NCT02911415
- Testing
- blood sampling collection
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Ebola, HIV/AIDS
Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy
Ebola and HIV are found predominately in the same regions of the world and countries in sub-Saharan Africa are most affected by both diseases. For Ebola, no approved therapies exist.
- Trial name
- RemTLAR (NCT04385719)
- Testing
- Remdesivir
- Where
- Uganda
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Makerere University